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Abstract 
With the advent of large-scale next generation sequencing initiatives, there is an 
increasing importance to interpret and understand the potential phenotypic influence 
of identified genetic variation and its significance in the human genome. 
Bioinformatics analyses can provide useful information to assist with variant 
interpretation. This review provides an overview of tools / resources currently 
available, and how they can help predict the impact of genetic variation at the DNA, 
RNA and protein level. 
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Introduction 
Clinical, diagnostic and research groups working in the field of hemostasis and 
thrombosis generate considerable data concerning genetic variation. Traditionally, 
this information has derived from targeted analysis of genes linked to a specific 
disease phenotype (e.g. investigating von Willebrand factor (VWF) in patients 
diagnosed with von Willebrand disease).1 Additional data also derives from genome-
wide association studies (GWAS) aimed at identifying genetic loci that may influence 
plasma protein levels2,3 or that are associated with a specific phenotype, e.g. 
coronary artery disease.4,5 The advent of next generation sequencing (NGS) has 
increased the amount of genetic information obtained from targeted analysis6-8 and is 
also generating a wealth of information on genetic variation throughout the human 
genome.9,10 
Although this information on genetic variation represents an invaluable resource, it is 
essential to properly interpret and understand the relevance of identified genetic 
variants within the human genome in order to determine whether they have a 
potential functional effect. Current guidelines from the American College of Medical 
Genetics and Genomics highlight that many lines of evidence are required to 
effectively classify genetic variants and assign pathogenicity,11 one of which is 
information obtained from bioinformatics analyses. This review aims to provide an 
overview of the many free in silico tools and resources currently available online that 
can help clinicians / scientists predict the potential impact of genetic variants at the 
DNA, RNA and protein level, and therefore assist with variant classification. 
 
Online resources for DNA level investigations 
Descriptions for the majority of reported genetic variants would usually be at the 
DNA level using either genomic coordinates (e.g. chr12:g.6044368T>C) or a specific 
location within a genetic locus (e.g. VWF:c.2365A>G). Usually, the first stage in 
evaluating genetic variants is to investigate the literature and databases for existing 
knowledge. 
 
Genome browsers and variant databases 
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Genome browsers (Ensembl, the National Center for Biotechnology Information 
(NCBI) Genome Data Viewer (GDV) and University of California Santa Cruz (UCSC) 
Genomics Institute (Table 1)) can be useful initial resources as they bring together 
extensive information on the human genome and other species. This includes 
information on known genetic variants, genotype-phenotype correlations, sequence 
conservation, transcription factor binding sites (TFBS) and expressed gene 
transcripts. These browsers also allow investigation of genetic variation at the 
precise nucleotide location or within the wider genomic context. While it may be 
difficult to identify relevant information on these browsers, especially for first-time 
users, useful tutorials on how to utilize Ensembl, GDV and UCSC are available 
online (Table 1). 
Several online variant databases detail the population frequency of genetic variants 
(Table 1). These resources provide indications of variant pathogenicity because 
common variants in the general population are generally less likely to be disease 
causing. However, variant frequencies can differ between ethnicities and frequency 
data may derive from disease-specific populations, which may influence data 
interpretation. The Exome Aggregation Consortium (ExAC) database and the 
Genome Aggregation Database (gnomAD) act as repositories of exonic and/or 
genomic sequencing data aligned to the human GRCh37/hg19 genome assembly.10 
Data derive from a variety of large-scale sequencing projects (e.g. 1000 Genomes) 
and various disease-specific population studies (e.g. the Framingham Heart Study), 
and includes populations from varying ethnicities. Currently, there is data from 
60,706 unrelated individuals in ExAC (including data on copy number variation 
[CNV]) and from 138,632 unrelated individuals (15,496 screened via whole genome 
sequencing) in gnomAD. 
NCBI also has databases of annotated genetic variant information, including 
population frequencies where available, which link to the various genome browsers. 
Information about simple genetic variation, including single nucleotide variants (SNV) 
and small insertion / deletion (indel) variants, catalogued in the database of single 
nucleotide polymorphisms (dbSNP; Table 1), are given rs# identifiers. Large CNV 
(>50 bp in length), catalogued in the database of human genomic structural variation 
(dbVar; Table 1), are given nsv# identifiers. Similar to dbVar, the Database of 
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Genomic Variants (DGV; Table 1) also provides annotated information on large CNV 
>50 bp in length. 
Another NCBI database, ClinVar (Table 1), links genetic variants with reported 
phenotypic information to provide an assessment of their clinical significance.12 Data 
included are derived from clinical testing, research or extraction from the literature. 
Of particular use, each entry has a confidence score, which reflects the accuracy of 
the variant information and the evidence supporting clinical significance. 
Similar to ClinVar, locus-specific databases (LSDBs) such as those for VWF13 and 
coagulation factor IX (F9)14 are highly useful clinical and scientific resources. LSDBs 
available through the Leiden Open Variation Database (LOVD) installation provide 
searchable lists of genetic variants and relevant phenotypic information where 
available (Table 1). However, many genes associated with hemostatic / thrombotic 
disorders currently have limited data available due to a lack of a dedicated curator(s) 
to help maintain and populate the relevant LOVD installation. A notable exception is 
the recent establishment of the European Association for Haemophilia and Allied 
Disorders Coagulation Factor Variant Databases (EAHAD-CFDB; Table 1). This 
initiative is a combined set of LSDBs (currently incorporating F7, F8, F9 and VWF) 
using LOVD installations to provide genotype-phenotype correlations while also 
establishing enhanced databases for each factor focusing on nucleotide / amino acid 
sequence conservation and protein structure.14,15 
 
Mutalyzer 
Mutalyzer (Table 1) is an online suite of tools that at a basic level are designed to 
help ensure that genetic variants are described correctly according to current Human 
Genome Variation Society guidelines,16,17 maintaining consistency in the reporting of 
variant descriptions. However, the tools also convert NCBI dbSNP identifiers (e.g. 
rs1063856) or genomic coordinates (e.g. chr12:g.6044368T>C; 
NC_000012.12:g.6044368T>C) to coding DNA nomenclature, which can be useful 
when working with variants identified via GWAS or NGS strategies. 
The conversion of genomic coordinates in Mutalyzer also provides an indication as 
to whether a variant could affect various expressed gene transcripts. Genes (e.g. F7, 
GP6 and FLI1) can have several transcripts that may vary in length, number of 
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exons and/or exon/intron boundaries. This can be particularly relevant when 
investigating genetic variants because a coding variant in one transcript may be non-
coding in another transcript (Figure 1) and alternate transcripts can have different 
patterns of tissue expression. 
 
Tools for assessing the potential impact of DNA variation 
Computational alignments of nucleotide or amino acid sequences can provide an 
indication as to whether specific regions have functional importance because these 
regions are likely to demonstrate high evolutionary conservation. Several online tools 
are available that can produce multiple sequence alignments (Table 1) and both the 
GDV and UCSC browsers can create alignments of up to 100 vertebrate species. 
GDV, UCSC and the Exome Variant Server (Table 1) also provide measurement 
scores of evolutionary conservation utilizing either phylogenetic analysis with 
space/time models conservation (phastCons), phylogenetic P-values (phyloP), 
genomic evolutionary rate profiling (GERP) and/or GERP++ predictions. phastCons 
provides probability scores from 0 to 1 that each nucleotide belongs to a conserved 
element based on multiple alignments and the flanking nucleotide sequence, where 
a score closer to 1 indicates greater conservation.18 phyloP assigns positive scores 
for conserved regions and negative scores for regions predicted to be evolving at a 
fast rate.19 Both GERP and GERP++ provide maximum likelihood evolutionary rate 
estimation scores from -12.3 to 6.17, with positive scores representing conserved 
regions.20,21 
Highly conserved regions may indicate the presence of important nucleotide motifs 
regulating transcription such as TFBS. Genetic variants occurring in these locations 
can influence gene expression (e.g. the well-characterized hemophilia B Leyden 
variants in F922 and c.-1522_-1510del variant in VWF).23 Several online tools 
(ConTra v3, GenomeTraFac, GPMiner; Table 1) will screen inputted nucleotide 
sequence and/or specified genomic regions and predict potential regulatory features. 
In addition, the Ensembl browser provides data on regulatory regions derived from 
the Blueprint, ENCODE and Roadmap Epigenomics projects and indicates the 
activity level of regulatory features in specific cells / tissues.24 Likewise, the UCSC 
browser also provides data derived from the ENCODE project25 along with 
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information from Open Regulatory Annotation26 and information on CpG islands 
(which can indicate potential transcription start sites27). 
Online resources are also beginning to evaluate gene intolerance to provide 
additional evidence of variant pathogenicity. For example, a gene that has a 
comparatively high frequency of variants predicted to result in loss-of-function (LoF, 
e.g. nonsense or splicing mutations) is less likely to have disease-causing variants 
(i.e. LoF tolerant). ExAC provides a probability of being LoF intolerant (pLI) value for 
each gene,10 dividing them into LoF intolerant (pLI ≥ 0.9) or LoF tolerant (pLI ≤ 0.1) 
categories. Similarly, the residual variation intolerance score (RVIS; Table 1) uses 
data derived from both ExAC and gnomAD to rank genes based on whether they 
have more or less common functional genetic variation relative to the genome-wide 
expectation.28 A negative RVIS score and low percentile highlights a gene with fewer 
common functional mutations than expected (LoF intolerant) while a positive score 
and high percentile highlights a LoF tolerant gene. 
 
Online resources for RNA level investigations 
Analysis of genetic variation at a RNA level primarily concerns those tools applicable 
to predicting their effect on RNA splicing. However, genetic variants can influence 
RNA in other ways, so additional tools / resources can also be of use. 
 
RNA splicing prediction tools 
Genetic variants that occur within consensus motifs for 5’ splice acceptors, 3’ splice 
donors or intronic branch points can interfere with the interaction of the spliceosome 
complex, influencing the splicing of intronic sequence from the mature RNA causing 
full / partial exon skipping29-32 or intron retention.30 In addition, deep intronic variants 
can activate cryptic splice acceptors or donors causing intron retention33 or the 
formation of a pseudo-exon.34,35 
There are several in silico tools available to help predict the effect of variants on 
RNA splicing (Table 2), usually based on the comparison of inputted wild-type and 
variant DNA sequence via specific algorithms. Although several tools utilize their 
own custom prediction algorithms (i.e. GeneSplicer, Human Splicing Finder (HSF) 
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and SplicePort),36-38 the majority use either maximum entropy modelling (MEM) or 
neural network algorithms.39-42 Each algorithm will interpret inputted DNA sequence 
differently; therefore, it is important to obtain a consensus from several RNA splicing 
tools in order to generate the most accurate predictions.43 However, even consensus 
predictions do not always signify a genuine effect on RNA splicing as has recently 
been observed for a c.5998+182A>G variant in F8.33 
The influence of genetic variants on RNA may be commonly overlooked, except 
when variants occur within introns or exon/intron boundaries. Analyzing variants in 
coding regions using in silico RNA splicing prediction tools should however be 
standard practice. There are several examples where synonymous variants31,44 and 
even coding variants predicted to influence the protein (e.g. resulting in a missense 
change45) disrupt splicing. Furthermore, in addition to the spliceosome interaction, 
serine-arginine repeat proteins and heterogeneous nuclear ribonucleoproteins act to 
promote and inhibit RNA splicing respectively.46 These proteins interact with the 
RNA via exonic / intronic splice enhancer (ESE / ISE) and exonic / intronic splice 
silencer (ESS / ISS) motifs. Genetic variants creating or disrupting these motifs can 
influence splicing47,48 and investigations including assessment of these motifs have 
begun in the field of hemostasis / thrombosis.49,50 
Currently, there are few in silico tools available to investigate whether variants create 
or disrupt enhancer / silencer motifs (Table 2). Both ESEfinder and RESCUE-ESE 
are limited because as their names suggest they focus only on ESE motif 
predictions. However, both SFmap and HSF provide enhancer and silencer motif 
predictions. As with regular RNA splicing in silico tools, consensus predictions from 
several tools are likely to be the most accurate, but given the limited tools available 
this is difficult to achieve when investigating enhancer / silencer motifs. 
As an initial tool to investigate the effect of genetic variants on RNA splicing, HSF is 
probably the most appropriate as it incorporates predictions for all motifs currently 
known to be involved in RNA splicing, including predictions from other sources (i.e. 
MEM algorithms, ESEfinder and RESCUE-ESE).38 HSF also allows for multiple input 
options and provides its own consensus prediction, but the use of additional tools is 
still likely to improve overall accuracy. 
Additional RNA prediction tools 
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Not all genetic variants will influence RNA splicing, but may still have an impact at 
the RNA level. Micro RNAs (miRNAs) play a role in regulating gene expression and 
studies have highlighted interactions with coagulation factors.51,52 A useful (regularly 
updated) online resource for investigating whether genetic variants influence 
reported / potential miRNA binding targets or generate a potential miRNA binding 
target is miRBase (Table 2). 
Genetic variants (e.g. c.2365A>G and c.2385T>C in VWF53) can also influence the 
secondary structure of transcribed mRNA, thereby impacting on the overall RNA 
stability, which in turn can influence RNA production.54 Rtools provides a useful suite 
of prediction programs designed to compare inputted wild-type and variant DNA 
sequence and to highlight any differences in RNA secondary structure (Table 2). 
The abundance of tRNA molecules available for a given amino acid codon sequence 
can affect the rate at which mature mRNA is translated into protein via a process 
called codon usage bias, and this in turn can be influenced by genetic variation. For 
example, a synonymous c.459G>A variant in F9 reduces factor IX translation rate 
partly via an effect on codon usage (as the non-reference valine codon is less 
abundant; GTG = 28.1 vs. GTA = 7.1 codons present per 1000 codons).55 Several 
online tools provide information on codon usage frequency or calculation of codon 
usage frequency either in the human genome or for a specific gene, e.g. Graphical 
Codon Usage Analyser (GCUA) and the Codon Usage Database (CUD; Table 2). 
 
Online resources for protein level investigations 
Analysis at the protein level utilizes those tools applicable to predicting the effect of 
non-synonymous amino acid variation and those resources that provide further 
information on the structure and function of proteins found to harbor potentially 
pathogenic variants. 
 
Amino acid prediction tools 
Non-synonymous amino acid substitutions can have profound effects on protein 
structure and function leading to disease. It is therefore useful to predict the impact 
of these changes on a protein in order to differentiate disease causing variants from  
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variants that have neutral effect.56 Several studies have demonstrated that variants 
affecting protein function are more frequently found at positions conserved 
throughout evolution.57 In addition, variants that affect protein stability are crucial for 
molecular function and are also more likely to be deleterious.58,59 Based on these 
assumptions, multiple prediction tools have been developed that use sequence 
and/or structural information to predict the pathogenicity of a given variant (Table 3). 
Two commonly used prediction algorithms include, sorting intolerant from tolerant 
(SIFT)60 and polymorphism phenotyping v2 (PolyPhen-2).61 SIFT is a popular 
prediction tool that utilizes sequence homology and the physical properties of amino 
acids to determine a variant’s impact.60 SIFT constructs a multiple sequence 
alignment (MSA) and then considers the composition of amino acids appearing at 
the site of the substitution. A SIFT score is then calculated, ranging from 0 to 1, 
reflecting the probability of the new amino acid being observed (tolerated) at that 
site. Scores ranging from 0 to 0.05 are considered to impact protein function. Other 
prediction tools incorporate the SIFT algorithm into their analysis pipelines, notably 
Mutation Predictor (MutPred) and nonsynonymous single nucleotide polymorphism 
analyzer (nsSNPAnalyzer; Table 3). 
PolyPhen-2 uses both sequence and structural information to predict the effect of a 
given variant.61 This is achieved by constructing a MSA, performing functional 
annotation of SNV, extracting protein sequence and structural information and 
building a conservation profile. Based on these properties PolyPhen-2 then 
estimates the probability that the missense mutation is ‘probably damaging’, 
‘possibly damaging’ or ‘benign’.62 
It is important to remember that each tool and the algorithm it employs will provide 
varying levels of prediction accuracy. When compared to known deleterious variants, 
impact predictions of most tools were found to be accurate in ~60-80% of cases.63 A 
recent study assessing the use of in silico tools to predict the pathogenicity of known 
deleterious variants in antithrombin found that performance varied depending on the 
localization of the substitution within the secondary structure, with those in α-helices 
often misclassified as benign.64 In addition, variants known to disrupt 
posttranslational modifications were also misclassified.64 As with RNA splicing 
predictions, it is therefore useful to utilize several prediction tools to achieve an 
accurate consensus (e.g. hemostasis / thrombosis studies investigating variants in 
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αIIbβ3, ADAMTS13, FVIII and VWF used MutationTaster, PolyPhen-2, PROVEAN 
and SIFT).7,65-68 
 
Tools for assessing protein stability 
The effect of an amino acid substitution on the protein stability and function is an 
important consideration when trying to determine pathogenicity. Using a protein 
databank (PDB) file and a specified variant, tools such as Site Directed Mutator 
(SDM; Table 3) can calculate a stability difference score between the wild-type and 
the variant protein.69 Where the tertiary structure of a protein of interest is unknown 
and no PDB structure file exists, machine learning programs such as MUpro (Table 
3) predict protein stability changes using primary sequence data alone.70 However, 
while these tools may be useful in a research context, providing an extra line of 
evidence, they do not make any predictions about whether a substitution is 
damaging or deleterious. 
 
Other useful protein tools and resources 
There are several resources that can be utilized in the analysis of proteins (e.g. to 
identify protein domains / motifs or to investigate protein-protein interactions). The 
Swiss Institute for Bioinformatics ExPASy resource (Table 3) contains a 
comprehensive list of protein analysis tools along with useful summary 
descriptions.71 PDB provides 3D protein models that when imported into specialized 
molecular graphics programs such as Jmol and PyMOL (Table 3) allows 
visualization of a variant at the molecular level (e.g. to elucidate the impact of a novel 
deletion in αIIbβ372) or simulate molecular interactions (e.g. to interpret variation in 
the DNA-binding domain of FLI173). This may be particularly useful to resolve 
instances of variant misclassification by amino acid prediction tools. For many 
proteins of interest, the 3D structure is currently unknown, so no PDB structure entry 
exists. In these instances computational homology based modelling servers such as 
SWISS-MODEL provide a useful alternative.74 
Variants causing amino acid substitutions in the signal peptide (SP) region of a 
protein may cause disruption or loss of function due to defective localization of the 
protein and/or defective SP cleavage. For secretory proteins therefore, it is important 
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to consider the effect of substitutions that occur in the SP region. The SignalP 4.1 
server (Table 3) predicts the presence and location of SP cleavage sites in an amino 
acid sequence and can predict the effect of substitutions or deletions/duplications on 
SP cleavage.75 
 
Additional tools / resources for variant analysis 
While most in silico tools focus on specific predictions at the DNA, RNA or protein 
level, Combined Annotation Dependent Depletion (CADD) and the Ensembl browser 
Variant Effect Predictor (VEP; Table 4) both use multiple lines of evidence to provide 
an assessment of variant pathogenicity. CADD integrates multiple and diverse 
annotations to produce a single measure of deleteriousness (C-score) for a particular 
SNV; a C-score of ≥10 indicates a variant is in the top 10% of the most deleterious, a 
score of ≥20 in the top 1%, etc.76 VEP provides a detailed annotation for variant 
effects on transcripts, proteins and regulatory regions, but is also a flexible and 
customizable software suite, allowing the addition of tools such as CADD into the 
analysis pipeline.77 However, while CADD and VEP can complement other 
predictions to provide further consensus, they are not stand-alone tools. 
Studies involving whole genome sequencing, whole exome sequencing (WES) or 
transcriptome profiling (using RNA sequencing or expression array approaches), 
generate large gene / protein lists. It is desirable to be able to make sense of these 
lists and extract the biological information they contain. The Database for Annotation, 
Visualization and Integrated Discovery (DAVID; Table 4) is a high-throughput and 
integrated data mining tool able to map genes / proteins to a biological annotation 
and then highlight statistically over-represented or enriched annotations.78 This can 
enable clustering of gene / protein lists to a range of criteria including diseases, 
functional categories, gene ontology terms, pathways, protein domains, protein 
interactions and tissue expression. 
Finally, the use of protein abundance information from different tissue types may be 
helpful when prioritizing candidate genes, e.g. to identify proteins present in the 
platelet proteome following WES of patients with inherited platelet function disorders. 
The Protein Abundance Database (PaxDb; Table 4) is a useful meta-resource of 
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protein abundance data for model organisms, tissues and cell-lines that enables a 
quick check of a protein of interest, aiding gene prioritization.79 
 
Concluding remarks 
In silico tools and online resources serve as useful sources of information for 
clinicians / scientists investigating genetic variation. However, this information is only 
a prediction and not a definitive answer; it will provide evidence to link a variant to 
disease pathogenicity or help confirm / direct further investigations, e.g. in vitro and 
in vivo studies. For the most accurate and informative analyses of a variant(s) users 
should consider its effect at the DNA, RNA and protein level (Figure 2) utilizing all 
the tools / resources highlighted in this review as a bioinformatics toolkit (Figure 3). 
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Tables 
Table 1. Tools / resources for investigating genetic variation at the DNA level 
Tool / resource Web address 
Genome browsers with multiple functionality 
Ensembl24 http://www.ensembl.org/index.html 
(online user guide: https://www.ensembl.org/info/website/tutorials/index.html) 
GDV80 https://www.ncbi.nlm.nih.gov/genome/gdv/ 
(online user guide: https://www.ncbi.nlm.nih.gov/genome/gdv/browser/help/) 
UCSC81 https://genome.ucsc.edu/cgi-bin/hgGateway 
(online user guide: https://genome.ucsc.edu/training/) 
Annotated genetic variation and population frequency databases 





Exome Variant Server http://evs.gs.washington.edu/EVS/ 
gnomAD10 http://gnomad.broadinstitute.org/ 




Sequence alignment toolsa 
Clustal Omega84 https://www.ebi.ac.uk/Tools/msa/clustalo/ 
MultAlin85 http://multalin.toulouse.inra.fr/multalin/ 
MUSCLE86 https://www.ebi.ac.uk/Tools/msa/muscle/ 
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Regulatory motif prediction tools 
ConTra v387 http://bioit2.irc.ugent.be/contra/v3/#/step/1 
GenomeTraFaC88 https://genometrafac.cchmc.org/genome-trafac/index.jsp 
GPMiner89 http://gpminer.mbc.nctu.edu.tw/index.php 






aTools that analyze both nucleotide and amino acid sequences.
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Table 2. Tools / resources for investigating genetic variation at the RNA level 
Tool / resource Web address 
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Table 3. Tools / resources for investigating genetic variation at the protein 
level 
Tool / resource Web address 









Tools for assessing protein stability 
MUpro70 http://mupro.proteomics.ics.uci.edu/ 
SDM69 http://marid.bioc.cam.ac.uk/sdm2 





SignalP 4.175 http://www.cbs.dtu.dk/services/SignalP/ 
SWISS-MODEL74 https://swissmodel.expasy.org 
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Table 4. Other useful tools / resources 







Figure 1. The location of genetic variants can vary depending on the gene 
transcript. A) Expressed gene transcripts for F7, GP6 and FLI1. Shaded boxes and 
vertical lines represent exonic sequence. B) Examples of genetic variants in F7, GP6 
and FLI1 are reported using genomic coordinates, and their corresponding location 
in each gene transcript. 
 
Figure 2. Example bioinformatics analyses for three sequence variants in VWF 
(A: c.55G>A, p.(Gly19Arg); B: c.2365A>G, p.(Thr789Ala); C: c.3614G>A, 
p.(Arg1205His)). Different analyses at the DNA (green), RNA (yellow) and protein 
(blue) level can each provide useful information concerning a sequence variant, and 
analyses at one level (e.g. DNA) may prompt additional analyses at the other two 
levels (e.g. RNA and protein). Tools such as CADD and VEP provide information 
relating to all three levels of analysis. aConsensus utilizing MutationTaster, 
PolyPhen-2, PROVEAN and SIFT. bConsensus utilizing ASSP, BDGP, HSF and 
NetGene2. cConsensus utilizing HSF, RESCUE-ESE and SFmap. ESS, exonic 
splice silencer; SE, splice enhancer; SS, splice silencer; WT, wild-type. 
 
Figure 3. A bioinformatics toolkit quick reference guide. Suggested analyses at 
the DNA (green), RNA (yellow) and protein (blue) level are highlighted, along with 
the tools / resources that could be used. 



